Komori
Management planning4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Notice Regarding the Consolidation of Manufacturing Sites

The company has decided to close the Mikasa Research Institute, one of the manufacturing sites for TGカイコサービス, at the end of May 2027 and consolidate its manufacturing operations at the Maebashi Research Institute. The company expects no impact on consolidated results for the fiscal year ending March 2027.

Worth reading
6Immaterial
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Items stated in the management plan

Date of board resolution15 September 2026
Publication date15 September 2026

This document does not state the plan name, plan period, or numerical targets.

Key initiatives
01Close the Mikasa Research Institute after completing manufacturing in May 2027
02Consolidate manufacturing operations at the Maebashi Research Institute
Items stated in the management plan
ItemDetails
Key initiativesClose the Mikasa Research Institute after completing manufacturing in May 2027, Consolidate manufacturing operations at the Maebashi Research Institute
Date of board resolution15 September 2026
Publication date15 September 2026
Items this document does not state (22)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identified

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company determined that reorganizing its manufacturing structure was essential in order to respond to soaring raw material and energy prices and changes in domestic and overseas demand, and to maintain and strengthen its earning power over the medium to long term. It aims to reduce manufacturing costs, improve manufacturing line utilization and optimize management resources.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Consolidation of Manufacturing Sites | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori